Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers

20 Nov 2007

Abstract excerpt

BACKGROUND: ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coronary syndromes. METHODS AND RESULTS: This was a randomized, double-blind, placebo-controlled study in 47 healthy volunteers of doses of ARC1779 from 0.05 to 1.0...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Complement system in diseases
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18025536
DOI: 10.1161/circulationaha.107.724864

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy VolunteersPMID 18025536Read ↗

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.Semantic proximity Read ↗

Antithrombotic and Prohemorrhagic Actions of Different Concentrations of Apixaban in Patients Exposed to Single and Dual Antiplatelet RegimensSemantic proximity Read ↗

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopeniaSemantic proximity Read ↗

Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks.Semantic proximity Read ↗

A First-in-human phase I study of an innovative selective inhibitor targeting coagulation factor XI/XIa in healthy volunteersSemantic proximity Read ↗

Functional Characterization of Antithrombin Mutations by Monitoring of Thrombin Inhibition Kinetics.Semantic proximity Read ↗

The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1Semantic proximity Read ↗

A Procoagulant Peptide Analog of the SARS-CoV-2 Nucleocapsid C-terminal DomainSemantic proximity Read ↗

Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.Semantic proximity Read ↗

Antithrombotic and anticoagulant effects of wild type and Gla-domain mutated human activated protein C in rats.Semantic proximity Read ↗

A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenolSemantic proximity Read ↗

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.